The University of Chicago Header Logo

Connection

Mary Rinella to Fatty Liver

This is a "connection" page, showing publications Mary Rinella has written about Fatty Liver.
Connection Strength

11.101
  1. Review Article: Fibrosis Reversal in Metabolic Dysfunction-Associated Steatohepatitis-The Promise of Emerging Therapeutics. Aliment Pharmacol Ther. 2026 Nov; 64(9):1184-1196.
    View in: PubMed
    Score: 0.869
  2. Therapeutic targets for metabolic dysfunction-associated steatohepatitis: a personalized approach to disease management. Nat Rev Gastroenterol Hepatol. 2026 Jun; 23(6):460-474.
    View in: PubMed
    Score: 0.845
  3. Variance Between Clinical Guidance and Real-World Management of Metabolic Dysfunction-associated Steatotic Liver Disease in the United States. Clin Gastroenterol Hepatol. 2025 Feb; 23(2):374-376.e3.
    View in: PubMed
    Score: 0.758
  4. Steatotic liver disease: a new name to reflect the combined role of alcohol and metabolic dysfunction. Nat Med. 2024 04; 30(4):933-936.
    View in: PubMed
    Score: 0.737
  5. Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition": EASL, AASLD and ALEH stand united to advance the field of steatotic liver disease. J Hepatol. 2024 07; 81(1):e20-e21.
    View in: PubMed
    Score: 0.723
  6. Defining an approach for therapeutic strategies in metabolic dysfunction-associated steatotic liver disease after liver transplantation. Hepatology. 2025 09 01; 82(3):766-776.
    View in: PubMed
    Score: 0.722
  7. Authors' response. J Acad Nutr Diet. 2013 Feb; 113(2):211-2.
    View in: PubMed
    Score: 0.340
  8. Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events. Hepatology. 2012 Nov; 56(5):1741-50.
    View in: PubMed
    Score: 0.334
  9. A myriad of pathways to NASH. Clin Liver Dis. 2012 Aug; 16(3):525-48.
    View in: PubMed
    Score: 0.326
  10. The role of diet and nutrient composition in nonalcoholic Fatty liver disease. J Acad Nutr Diet. 2012 Mar; 112(3):401-9.
    View in: PubMed
    Score: 0.319
  11. Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease? Hepatology. 2011 Oct; 54(4):1118-20.
    View in: PubMed
    Score: 0.310
  12. Dysregulation of the unfolded protein response in db/db mice with diet-induced steatohepatitis. Hepatology. 2011 Nov; 54(5):1600-9.
    View in: PubMed
    Score: 0.306
  13. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol. 2011 Jul-Sep; 10(3):277-86.
    View in: PubMed
    Score: 0.305
  14. Non-alcoholic fatty liver disease: is bariatric surgery the answer? Clin Liver Dis. 2009 Nov; 13(4):689-710.
    View in: PubMed
    Score: 0.271
  15. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res. 2008 May; 49(5):1068-76.
    View in: PubMed
    Score: 0.240
  16. The dynamic spectrum of steatotic liver disease: the global perspective. Nat Rev Gastroenterol Hepatol. 2026 Nov; 23(11):812-829.
    View in: PubMed
    Score: 0.217
  17. Clinical Outcomes and Non-Invasive Testing in Metabolic Dysfunction-Associated Steatohepatitis With Cirrhosis: A Systematic Review. Liver Int. 2026 05; 46(5):e70608.
    View in: PubMed
    Score: 0.213
  18. Comparative efficacy of phase 2-3 therapies for non-cirrhotic metabolic dysfunction-associated steatohepatitis: An updated network meta-analysis. Med. 2026 May 08; 7(5):101077.
    View in: PubMed
    Score: 0.212
  19. The Relentless Progression of Metabolic Dysfunction-associated Steatotic Liver Disease in Liver Transplantation in Spain. Transplantation. 2026 Feb 01; 110(2):e444-e452.
    View in: PubMed
    Score: 0.206
  20. Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial. Aliment Pharmacol Ther. 2025 Dec; 62(11-12):1089-1099.
    View in: PubMed
    Score: 0.205
  21. Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2025 11; 10(11):998-1012.
    View in: PubMed
    Score: 0.204
  22. Phosphatidylethanol in steatotic liver disease. J Hepatol. 2025 Nov; 83(5):1189-1203.
    View in: PubMed
    Score: 0.202
  23. Call to action-Pediatric MASLD requires immediate attention to curb health crisis. Hepatology. 2025 11 01; 82(5):1341-1351.
    View in: PubMed
    Score: 0.201
  24. Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis. J Gastroenterol. 2025 07; 60(7):891-904.
    View in: PubMed
    Score: 0.197
  25. Metabolic dysfunction-associated steatotic liver disease in adults. Nat Rev Dis Primers. 2025 Mar 06; 11(1):14.
    View in: PubMed
    Score: 0.197
  26. Risk Stratification for Chronic Kidney Disease After Liver Transplant for Metabolic Dysfunction-associated Steatohepatitis (MASH) Cirrhosis: Results From the NailMASH Consortium. Transplantation. 2025 03 01; 109(3):484-495.
    View in: PubMed
    Score: 0.192
  27. Validating the new nomenclature of steatotic liver disease in patients with excessive alcohol intake - Authors' reply. Lancet Gastroenterol Hepatol. 2024 05; 9(5):409-410.
    View in: PubMed
    Score: 0.185
  28. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol Hepatol. 2024 03; 9(3):218-228.
    View in: PubMed
    Score: 0.182
  29. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol. 2004 Jan; 40(1):47-51.
    View in: PubMed
    Score: 0.181
  30. Reply to: "From NAFLD to MASLD: Promise and pitfalls of a new definition'. Ann Hepatol. 2024 Jul-Aug; 29(4):101178.
    View in: PubMed
    Score: 0.181
  31. Steatotic liver disease, a useful construct in primary care that doesn't upset the apple cart. Hepatology. 2024 06 01; 79(6):1252-1254.
    View in: PubMed
    Score: 0.181
  32. Dual-echo, chemical shift gradient-echo magnetic resonance imaging to quantify hepatic steatosis: Implications for living liver donation. Liver Transpl. 2003 Aug; 9(8):851-6.
    View in: PubMed
    Score: 0.176
  33. Body mass index as a predictor of hepatic steatosis in living liver donors. Liver Transpl. 2001 May; 7(5):409-14.
    View in: PubMed
    Score: 0.151
  34. Editorial: Age and Non-Invasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease: Time to Adjust the Clock? Am J Gastroenterol. 2017 05; 112(5):752-754.
    View in: PubMed
    Score: 0.114
  35. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015 Jun 09; 313(22):2263-73.
    View in: PubMed
    Score: 0.100
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.